<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248170/" ref="ordinalpos=3040&amp;ncbi_uid=3763748&amp;link_uid=PMC3248170" image-link="/pmc/articles/PMC3248170/figure/F1/" class="imagepopup">Figure 1. Mechanisms of acquired resistance to BRAF and MEK inhibitors in BRAF mutant cancers.  From: Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. </a></div><br /><div class="p4l_captionBody">A schematic of the RAF-MEK-ERK signaling pathway is shown with BRAF in red. Alterations of signaling pathway components leading to resistance to BRAF or MEK inhibitors are indicated by number. Resistance mechanisms classified as ERK-dependent are shown in the left panel, and mechanisms classified as ERK-independent are shown in the right panel.</div></div>